Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857415 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
A Phase 3 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 226
- Enrollment target
NCT00857415 is a Phase 3 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 226 participants.
The verdict
NCT00857415, a Phase 3 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 226 participants
- Enrollment target
Study Summary
The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy. Amyloid in the brain is a key feature of Alzheimer's Disease (AD).
Interventions
- DRUG florbetapir F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00857415
The ClinicalTrials.gov registry entry for NCT00857415 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which florbetapir F 18 is the first listed.
NCT00857415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00857415 about?
NCT00857415 is a clinical study titled "Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain". The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy. Amyloid in the brain is a key feature of Alzheimer's Disease (AD).
What is the current status of trial NCT00857415?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 226 participants. The study started on 2008-12. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00857415?
The interventions under investigation include: florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT00857415?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.